We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Veradigm Inc | NASDAQ:MDRX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.81 | 6.85 | 6.90 | 0 | 01:00:00 |
|
2bPrecise is now giving physicians across the country the ability to practically apply precision medicine to diagnose and treat their patients. National Institutes of Health and Holston Medical Group are currently participating in early adopter programs. By delivering understandable and actionable genomic insights into physicians’ existing clinical workflows, the platform enables informed decision-making in an effort to improve outcomes and reduce costs.
“As the pace of genomic discovery continues to accelerate, the mountain of genetic data – separated in clinical, lab or other systems – continues to grow,” said Assaf Halevy, founder and CEO of 2bPrecise. “For patients to benefit from this expanding body of knowledge, we need to get the relevant insights into the hands of treating providers without disrupting their existing workflows. 2bPrecise is the last-mile solution that closes this information gap, empowering physicians to provide the most precise care.”
A wholly owned subsidiary of Allscripts Healthcare Inc., 2bPrecise’s vendor-neutral solution is uniquely positioned for success. “Allscripts prides itself on its reputation for investing in open platforms driven by entrepreneurial leaders, with the goal of helping providers regardless of their current HCIT platform,” said Paul Black, CEO of Allscripts. “Our support of 2bPrecise is no exception, and we are committed to helping cultivate its innovative approach to precision medicine; making genomic insights actionable and accessible for providers.”
Key components of the 2bPrecise platform include:
To learn more, visit 2bPrecise at HIMSS booth #6045.
About 2bPrecise 2bPrecise harnesses the power of genomics and precision medicine in an effort to precisely predict and efficiently treat each individual patient. 2bPrecise’s EHR-agnostic, cloud-based platform captures and stores genomic data and harmonizes it with research knowledge and clinical information. The resulting actionable insights are then pushed into a provider’s existing clinical workflow to facilitate decision-making at the point of care. Learn more at www.2bPrecisehealth.com.
About AllscriptsAllscripts (NASDAQ:MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.
Media Contact: Danielle Johns Aria Marketing for 2bPrecise djohns@ariamarketing.com 617-332-9999 x241 Concetta Rasiarmos Allscripts Public Relations concetta.rasiarmos@allscripts.com 630-740-3152 Investors: Seth Frank Allscripts Vice President of Investor Relations 312-506-1213 seth.frank@allscripts.com
1 Year Veradigm Chart |
1 Month Veradigm Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions